	US 11,911,472 B2
	Monoclonal antibody and vaccine targeting filamentous bacteriophage
Paul L. Bollyky, Stanford, CA (US); William Parks, Seattle, WA (US); and Patrick Secor, Seattle, WA (US)
Assigned to INIMMUNE CORPORATION, Missoula, MT (US)
Filed by INIMMUNE CORPORATION, Missoula, MT (US)
Filed on Oct. 8, 2020, as Appl. No. 17/066,005.
Application 17/066,005 is a continuation of application No. 16/262,548, filed on Jan. 30, 2019, granted, now 10,835,607.
Application 16/262,548 is a continuation of application No. 15/219,073, filed on Jul. 25, 2016, abandoned.
Claims priority of provisional application 62/196,147, filed on Jul. 23, 2015.
Prior Publication US 2021/0030875 A1, Feb. 4, 2021
Int. Cl. A61K 39/104 (2006.01); A61K 47/64 (2017.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 16/08 (2006.01)

CPC A61K 45/06 (2013.01) [A61K 39/104 (2013.01); A61K 47/646 (2017.08); C07K 16/08 (2013.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01)]

1 Claim

1. A method of making an antiserum containing antibodies specific to a CoaB coat protein of the Pf-family bacteriophage, the method comprising immunizing an animal or human subject by administering to the subject a vaccine against the Pf-family bacteriophage, the vaccine comprising

(a) an immunogenic fragment of the CoaB coat protein of the Pf-family bacteriophage consisting of the amino acid sequence GVIDTSAVESAITDGQGDM (SEQ ID NO: 1) conjugated to an immunogenic protein, and

(b) a pharmaceutically acceptable carrier.